Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B A Pulaski

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Cancer Research|April 16, 1998
Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccinesB A Pulaski, S Ostrand-Rosenberg
Current Protocols in Immunology|April 25, 2008
Mouse 4T1 breast tumor modelB A Pulaski, S Ostrand-Rosenberg
Molecular and Cellular Biology|November 11, 1991
Assembly of 60S ribosomal subunits is perturbed in temperature-sensitive yeast mutants defective in ribosomal protein L16M Moritz, B A Pulaski, J L Woolford
Cancer Immunology, Immunotherapy : CII|April 29, 1998
Tumor antigen presentation: changing the rulesT D Armstrong, B A Pulaski, S Ostrand-Rosenberg
Advances in Experimental Medicine and Biology|February 23, 1999
Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccinesS Ostrand-Rosenberg, B A Pulaski, T D Armstrong, et al.
Cancer Immunology, Immunotherapy : CII|April 27, 2000
Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gammaB A Pulaski, V K Clements, M R Pipeling, et al.
Cancer Research|May 29, 2000
Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer modelB A Pulaski, D S Terman, S Khan, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1993
Interleukin-3 inhibits the generation of nonspecific killers by interleukin-2A J McAdam, K Y Yeh, B A Pulaski, et al.
Cancer Research|May 1, 1993
Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanismB A Pulaski, A J McAdam, E K Hutter, et al.
Immunological Reviews|November 24, 1999
Cell-based vaccines for the stimulation of immunity to metastatic cancersS Ostrand-Rosenberg, B A Pulaski, V K Clements, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Cancer Research|April 16, 1998
Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccinesB A Pulaski, S Ostrand-Rosenberg
Current Protocols in Immunology|April 25, 2008
Mouse 4T1 breast tumor modelB A Pulaski, S Ostrand-Rosenberg
Molecular and Cellular Biology|November 11, 1991
Assembly of 60S ribosomal subunits is perturbed in temperature-sensitive yeast mutants defective in ribosomal protein L16M Moritz, B A Pulaski, J L Woolford
Cancer Immunology, Immunotherapy : CII|April 29, 1998
Tumor antigen presentation: changing the rulesT D Armstrong, B A Pulaski, S Ostrand-Rosenberg
Advances in Experimental Medicine and Biology|February 23, 1999
Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccinesS Ostrand-Rosenberg, B A Pulaski, T D Armstrong, et al.
Cancer Immunology, Immunotherapy : CII|April 27, 2000
Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gammaB A Pulaski, V K Clements, M R Pipeling, et al.
Cancer Research|May 29, 2000
Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer modelB A Pulaski, D S Terman, S Khan, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1993
Interleukin-3 inhibits the generation of nonspecific killers by interleukin-2A J McAdam, K Y Yeh, B A Pulaski, et al.
Cancer Research|May 1, 1993
Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanismB A Pulaski, A J McAdam, E K Hutter, et al.
Immunological Reviews|November 24, 1999
Cell-based vaccines for the stimulation of immunity to metastatic cancersS Ostrand-Rosenberg, B A Pulaski, V K Clements, et al.
Pageof 2